Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.50 |
| ▸ | WDR91 | A4D1P6 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | DHPS | P49366 | 1/20 | 0.45 |
| ▸ | AHR | P35869 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9836689 | 0.84 | CRBN (0.49) | CRBNWDR91DHPSAHRPDK2 | |
| SCHEMBL9375284 | 0.84 | CRBN (0.49) | CRBNWDR91DHPSAHRPDK2 | |
| SCHEMBL9294186 | 0.84 | MEN1 (0.47) | CRBNMEN1KMT2AHTR1AOPRK1 | |
| SCHEMBL9836593 | 0.83 | CRBN (0.46) | CRBNWDR91DHPSAHRPDK2 | |
| SCHEMBL5362141 | 0.80 | CCNB2 (0.48) | CRBNWDR91DHPSCCNB2CDK1 | |
| SCHEMBL496850 | 0.79 | TRPA1 (0.49) | CRBNMEN1KMT2AAHRPDK2 | |
| SCHEMBL4410729 | 0.79 | DRD2 (0.50) | CRBNWDR91DHPSCCNB2CDK1 | |
| SCHEMBL5840685 | 0.77 | WDR91 (0.51) | CRBNWDR91DHPSDRD2DRD4 | |
| SCHEMBL5893591 | 0.77 | TSHR (0.51) | CRBNWDR91CCNB2CDK1CCNB1 | |
| SCHEMBL15823360 | 0.76 | P2RX7 (0.55) | CRBNWDR91MEN1KMT2ADHPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2004-07-29 | — | — | US | claimed |
| EP-1294688-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | Sugen, Inc. (US) | 2003-03-26 | — | — | EP | claimed |
| US-20020052369-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2002-05-02 | — | — | US | claimed |
| WO-2001094312-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | SUGEN, INC. (US) | 2001-12-13 | — | — | WO | claimed |
| EP-0344634-B1 | Bicyclic carboxamides, process for their preparation and medicaments containing them | BOEHRINGER MANNHEIM GMBH (DE) | 1994-03-30 | — | — | EP | claimed |
| CN-1038640-A | Two ring carboxamide, its preparation methods and contain the pharmaceutical composition of this material | BOEHRINGER MANNHEIM GMBH (DE) | 1990-01-10 | — | — | CN | claimed |
| EP-4540238-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | Monte Rosa Therapeutics AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| US-20250115582-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-04-10 | — | — | US | disclosed |
| CN-119751456-A | Spiro compounds | C4医药公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-112312904-B | Spiro compounds | C4医药公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20240400513-A1 | NOVEL COMPOUNDS | UCL BUSINESS LTD (GB) | 2024-12-05 | — | — | US | disclosed |
| WO-2024107778-A1 | NOVEL PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-05-23 | — | — | WO | disclosed |
| US-11919856-B2 | Compounds | UCL BUSINESS LTD (GB) | 2024-03-05 | — | — | US | disclosed |
| CN-1044243-C | Biphenyl-substituted quinoline derivatives | SQUIBB & SONS INC (US) | 1999-07-21 | — | — | CN | disclosed |
| WO-1998050356-A1 | 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY | SUGEN, INC. (US) | 1998-11-12 | — | — | WO | disclosed |
| EP-0344634-B1 | Bicyclic carboxamides, process for their preparation and medicaments containing them | BOEHRINGER MANNHEIM GMBH (DE) | 1994-03-30 | — | — | EP | disclosed |
| CN-1075720-A | The quinoline that xenyl replaces | SQUIBB & SONS INC (US) | 1993-09-01 | — | — | CN | disclosed |
| EP-0556060-A1 | Biphenyl-substituted quinoline and naphthyridines derivatives as angiotensine II antagonists | E.R. SQUIBB & SONS, INC. (US) | 1993-08-18 | — | — | EP | disclosed |
| US-5019587-A | Anticoagulants | BOEHRINGER MANNHEIM GMBH (DE) | 1991-05-28 | — | — | US | disclosed |
| EP-0344634-A1 | Bicyclic carboxamides, process for their preparation and medicaments containing them | Roche Diagnostics GmbH (DE) | 1989-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400513-A1 | NOVEL COMPOUNDS | SERPINC1, SERPINA2, SERPINA3 | CRBN 3837/4885WDR91 4033/4885MEN1 493/4885 |
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | PHKA1, PHKA2, PDPK1 | CRBN 1979/4885WDR91 3052/4885MEN1 4188/4885 |
| US-11919856-B2 | Compounds | SERPINC1, SERPINA2, SERPINA3 | CRBN 3802/4885WDR91 4574/4885MEN1 262/4885 |
| US-20250115582-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | CRBN 226/4885WDR91 667/4885MEN1 2589/4885 |
| US-20020052369-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | PHKA1, PHKA2, PDPK1 | CRBN 1979/4885WDR91 3052/4885MEN1 4188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.